Trial Profile

A Phase 3 Clinical Study Evaluating the Long-term Efficacy and Safety of AK102 in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ebronucimab (Primary)
Indications Hypercholesterolaemia; Hyperlipoproteinaemia type V
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Akeso Biopharma

Most Recent Events

28 Feb 2025 Status changed from recruiting to completed.
30 Sep 2024 According to Akeso Biopharma media release, National Medical Products Administration (NMPA) of China has approved the new drug application (NDA) of (ebronucimab, PCSK9) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolaemia (HeFH), based on results from this study.
28 Feb 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com